Immune checkpoint programmed death-ligand 1 (PDL-1) inhibitor therapy has shown response in metastatic muscle invasive bladder cancer (MIBC). We evaluated the safety and tolerability of atezolizumab (anti-PDL-1) in combination with trimodal therapy (TMT) in patients with localized MIBC.